Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: Potential role of human papilloma virus infection

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages

  Le Boeuf, Fabrice ^a,b   Niknejad, Nima ^a,b   Wang, Jiahu ^a,b   Auer, Rebecca ^a,b   Weberpals, Johanne I ^a,b   Bell, John C ^a,b   Dimitroulakos, Jim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

cervical cancer; human papilloma virus (HPV); interferon; oncolytics; vesicular stomatitis virus (VSV)

Indexed keywords

INTERFERON; INTERFERON RECEPTOR; ONCOLYTIC VIRUS; PROTEIN E6;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXICITY; DISEASE MODEL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; WART VIRUS;

ANIMALS; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERFERONS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 84862799997     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27404     Document Type: Review

References (45)

1. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G,. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H,. Classification of papillomaviruses. Virology 2004; 324: 17-27.
3. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL,. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24 (Suppl 3): S3/26-S3/34.
4. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
5. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M,. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010; 40: 1-13.
6. McLaughlin-Drubin ME, Munger K,. Oncogenic activities of human papillomaviruses. Virus Res 2009; 143: 195-208.
7. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A, Zehbe I,. The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003; 21: 307-12.
8. Tommasino M, Crawford L,. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays 1995; 17: 509-18.
9. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, Matlashewski GJ, Koromilas AE,. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α. Oncogene 1999; 18: 5727-37.
10. Greenlee RT, Murray T, Bolden S, Wingo PA,. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
11. Bell JC,. Oncolytic viruses: what's next? Curr Cancer Drug Targets 2007; 7: 127-31.
12. Parato KA, Senger D, Forsyth PA, Bell JC,. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-76.
13. Crompton AM, Kirn DH,. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007; 7: 133-9.
14. Russell SJ, Peng KW,. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-33.
15. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-42.
16. Liu TC, Hwang T, Park BH, Bell J, Kirn DH,. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-42.
17. Kirn D,. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8: 89-98.
18. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J,. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009; 9: 422-7.
19. Opyrchal M, Aderca I, Galanis E,. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol 2009; 542: 705-17.
20. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC,. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-5.
21. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-75.
22. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC,. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004; 15: 821-31.
23. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M,. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918-21.
24. Balachandran S, Porosnicu M, Barber GN,. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001; 75: 3474-9.
25. Barber GN,. VSV-tumor selective replication and protein translation. Oncogene 2005; 24: 7710-19.
26. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH,. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4: e353.
27. Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-β for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther 2010; 21: 51-64.
28. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG,. Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009; 69: 7713-20.
29. Enninga J, Levy DE, Blobel G, Fontoura BM,. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 2002; 295: 1523-5.
30. Her LS, Lund E, Dahlberg JE,. Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science 1997; 276: 1845-8.
31. Stanley MA, Pett MR, Coleman N,. HPV: from infection to cancer. Biochem Soc Trans 2007; 35: 1456-60.
32. Woodworth CD,. HPV innate immunity. Front Biosci 2002; 7: d2058-d2071.
33. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM,. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36: 3020-7.
34. Li GL, Jiang W, Xia Q, Chen SH, Ge XR, Gui SQ, Xu CJ,. HPV E6 down-regulation and apoptosis induction of human cervical cancer cells by a novel lipid-soluble extract (PE) from Pinellia pedatisecta Schott in vitro. J Ethnopharmacol 2010; 132: 56-64.
35. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15: 1686-93.
36. Stertz S, Dittmann J, Blanco JC, Pletneva LM, Haller O, Kochs G,. The antiviral potential of interferon-induced cotton rat Mx proteins against orthomyxovirus (influenza), rhabdovirus, and bunyavirus. J Interferon Cytokine Res 2007; 27: 847-55.
37. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL,. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-7.
38. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC,. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-9.
39. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL,. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-43.
40. Naik S, Russell SJ,. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009; 9: 1163-76.
41. Prestwich R, Vile R, Melcher A,. Cancer immunotherapy. N Engl J Med 2008; 359: 1072; author reply 3.
42. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG,. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009; 20: 1119-32.
43. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F,. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008; 8: 1581-8.
44. Lichty BD, Power AT, Stojdl DF, Bell JC,. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004; 10: 210-16.
45. Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010; 18: 888-95.